Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of December 2021
Date of Report: December 2, 2021
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves to incorporate by reference a press release dated December 2, 2021 (Exhibit 99.1) into the company's registration statement on Form F-3 (File No. 333-252074). The document is signed by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a cover sheet for a press release and does not include revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific content of the referenced press release (Exhibit 99.1) is not included in the input text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or descriptions of unusual items. These details would be contained within the referenced Exhibit 99.1 press release, which is not provided in the source text.
Investor Verification Checklist
- Verify the specific content of the press release dated December 2, 2021 (Exhibit 99.1) referenced in this filing.
- Confirm the status of the Form F-3 registration statement (File No. 333-252074) into which this report is incorporated.
- Review subsequent filings to determine if the information in this press release has been superseded.